argenx SE Expected to Post Q2 2024 Earnings of $0.07 Per Share (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – William Blair raised their Q2 2024 earnings per share estimates for shares of argenx in a research note issued to investors on Monday, June 24th. William Blair analyst M. Minter now expects that the company will post earnings of $0.07 per share for the quarter, up from their previous forecast of $0.06. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for argenx’s current full-year earnings is ($2.89) per share. William Blair also issued estimates for argenx’s Q1 2025 earnings at $0.58 EPS, Q2 2025 earnings at $0.89 EPS, Q3 2025 earnings at $1.46 EPS, Q4 2025 earnings at $1.88 EPS, FY2025 earnings at $4.75 EPS and FY2026 earnings at $15.84 EPS.

argenx (NASDAQ:ARGX) last posted its quarterly earnings results on Monday, May 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.33). The company had revenue of $412.51 million for the quarter, compared to analyst estimates of $404.03 million. argenx had a negative return on equity of 14.14% and a negative net margin of 22.58%. During the same period last year, the firm earned ($0.52) EPS.

ARGX has been the topic of a number of other reports. JPMorgan Chase & Co. decreased their target price on argenx from $560.00 to $500.00 and set an “overweight” rating on the stock in a report on Monday, May 13th. Scotiabank upped their price objective on argenx from $402.00 to $408.00 and gave the company a “sector perform” rating in a report on Tuesday, March 26th. JMP Securities decreased their price objective on argenx from $471.00 to $468.00 and set a “market outperform” rating on the stock in a report on Friday, May 10th. Stifel Nicolaus upped their price objective on argenx from $485.00 to $500.00 and gave the company a “buy” rating in a report on Monday. Finally, Wedbush reaffirmed an “outperform” rating and issued a $519.00 price objective on shares of argenx in a report on Wednesday. Five analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $525.42.

argenx Trading Down 0.2 %

ARGX stock opened at $444.94 on Wednesday. The firm has a market capitalization of $26.44 billion, a PE ratio of -78.61 and a beta of 0.65. argenx has a 1-year low of $327.73 and a 1-year high of $550.76. The business’s 50 day simple moving average is $381.58 and its 200 day simple moving average is $387.30.

Institutional Trading of argenx

Several institutional investors and hedge funds have recently modified their holdings of ARGX. Price T Rowe Associates Inc. MD lifted its position in shares of argenx by 49.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock worth $2,167,235,000 after buying an additional 1,830,651 shares during the last quarter. Capital World Investors lifted its position in shares of argenx by 37.0% during the 4th quarter. Capital World Investors now owns 1,961,202 shares of the company’s stock worth $746,099,000 after buying an additional 530,181 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of argenx by 24.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock worth $872,690,000 after buying an additional 439,889 shares during the last quarter. Artisan Partners Limited Partnership lifted its position in shares of argenx by 12.2% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,174,477 shares of the company’s stock worth $1,207,666,000 after buying an additional 346,178 shares during the last quarter. Finally, Avoro Capital Advisors LLC raised its position in argenx by 23.5% in the fourth quarter. Avoro Capital Advisors LLC now owns 1,234,567 shares of the company’s stock valued at $469,666,000 after purchasing an additional 234,567 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.